One of Mobius Medical’s proudest collaborations is with Saluda Medical, a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry through patented Evoke Closed-Loop Chronic Pain Therapy technology based on the evoked compound action potential (ECAP).

Australian CRO for their CE Mark study “Avalon” in 2015 to 2019, Mobius continues to support Saluda Medical in Australia with ongoing trials in the post market space. We’re absolutely thrilled by the news on 8 March 2022 of full approval from the United States Food and Drug Administration (FDA) for the Evoke® Spinal Cord Stimulation (SCS) System. Read more here